Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLG2071 vs Cleviprex in hypertensive emergencies
CTR20231630Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clevidipine in hypertensive emergency, hypertensive urgency, sponsored by Qilu Pharmaceutical. Started Jun 2023; status: completed.
02
Drugs
clevidipine
03
Conditions
hypertensive emergencyhypertensive urgency
Beyond the preview
Go deeper on CTR20231630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231630.